Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma
Highly Entrenched Rituxan Could Prove Tough To Dislodge
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
You may also be interested in...
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.